SEC Comment Letter 0000000000-23-009206 to Scinai Immunotherapeutics Ltd. (SCNI)

Scinai Immunotherapeutics Ltd.
Date: Aug. 22, 2023 · CIK: 0001611747 · Accession: 0000000000-23-009206

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-274078

Date

August 22, 2023

Author

Cindy Polynice

Form

UPLOAD

Company

Scinai Immunotherapeutics Ltd.

Letter

United States securities and exchange commission logo August 22, 2023 Amir Reichman Chief Executive Officer BiondVax Pharmaceuticals Ltd. Jerusalem BioPark, 2nd Floor Kiryat Hadassah, Building 1, JBP Jerusalem, Israel 9112001 Re:BiondVax Pharmaceuticals Ltd. Registration Statement on Form F-3 Filed on August 18, 2022 File No. 333-274078 Dear Amir Reichman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Perry Wildes, Esq.

Show Raw Text

United States securities and exchange commission logo
August 22, 2023
Amir Reichman
Chief Executive Officer
BiondVax Pharmaceuticals Ltd.
Jerusalem BioPark, 2nd Floor
Kiryat Hadassah, Building 1, JBP
Jerusalem, Israel 9112001
Re:BiondVax Pharmaceuticals Ltd.
Registration Statement on Form F-3
Filed on August 18, 2022
File No. 333-274078
Dear Amir Reichman:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Perry Wildes, Esq.

SecProbe.io